Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Alexion Pharmaceuticals, Inc.    ALXN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/22/2017 03/23/2017 03/24/2017 03/27/2017 03/28/2017 Date
120.08(c) 120.26(c) 119.26(c) 118.83(c) 118.53(c) Last
1 394 955 1 409 885 1 292 350 2 400 467 1 115 367 Volume
+1.16% +0.15% -0.83% -0.36% -0.25% Change
More quotes
Financials ($)
Sales 2017 3 481 M
EBIT 2017 1 440 M
Net income 2017 755 M
Debt 2017 986 M
Yield 2017 -
Sales 2018 4 063 M
EBIT 2018 1 812 M
Net income 2018 1 046 M
Debt 2018 871 M
Yield 2018 -
P/E ratio 2017 35,20
P/E ratio 2018 25,80
EV / Sales2017 7,93x
EV / Sales2018 6,77x
Capitalization 26 623 M
More Financials
Company
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products.Its products include soliris, strensiq and kanuma.The company... 
Sector
Pharmaceuticals
Calendar
04/27Earnings Release
More about the company
Surperformance© ratings of Alexion Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on ALEXION PHARMACEUTICALS, I
03/27DJALEXION PHARMACEUTICALS : Names New CEO Following Internal Sales-Practice Probe
03/27 ALEXION PHARMACEUTICALS INC : Change in Directors or Principal Officers, Financi..
03/27 ALEXION PHARMACEUTICALS : Appoints Ludwig Hantson, Ph.D., as Chief Executive Off..
03/22 ALEXION PHARMACEUTICALS : Submits Application in Japan for Soliris® (Eculizumab)..
03/17 ALEXION PHARMACEUTICALS : ALXN) Flat on Arbutus Deal
03/16 ALEXION PHARMACEUTICALS : FDA Accepts sBLA Filing of Soliris® Eculizumab as a Po..
03/15 ALEXION PHARMACEUTICALS : in New Haven to lay off 210 employees
03/11 ALEXION PHARMACEUTICALS : Bellerophon Therapeutics, Inc. (BLPH)
03/08 ALEXION PHARMACEUTICALS : FDA Accepts sBLA Filing of Soliris® (Eculizumab) as a ..
03/03 ALEXION PHARMACEUTICALS : Board Plans To Appoint David Brennan To Succeed Bell A..
More news
Sector news : Biopharmaceuticals
03/28DJSenator McCaskill Begins Probe of Prescription Opioid Marketing -- 2nd Update
03/28DJSHIRE : Files 8K - Other Events
03/28DJSenator McCaskill Begins Probe of Prescription Opioid Marketing -- Update
03/28DJSenator McCaskill Begins Probe of Prescription Opioid Marketing
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
More sector news : Biopharmaceuticals
Latest Tweets
03/28Alexion brings on former Baxalta chief Hantson to fill vacant CEO spot  
03/28Alexion brings on former Baxalta chief Hantson to fill vacant CEO spot  
03/28New Haven-based Alexion names new chief executive
1
03/27Alexion Pharmaceuticals's outperform rating reiterated at Royal Bank of Canad..
1
03/27#2 - UPDATED: Ex-Baxalta CEO Ludwig Hantson gets the top job at a troubled Al..
1
More tweets
Qtime:158
News from SeekingAlpha
03/27 My Favorite Biotech Takeover Play
03/27 New chief at Alexion
03/25 MARKETPLACE ROUNDTABLE : Biotech Hanging In The Balance
03/22 Alexion submits Soliris marketing application in Japan for myasthenia gravis;..
03/22 Best Price-Positioned Integrated Oil & Gas Stocks, As Seen By Market-Makers
Advertisement
Chart ALEXION PHARMACEUTICALS, I
Duration : Period :
Alexion Pharmaceuticals, I Technical Analysis Chart | ALXN | US0153511094 | 4-Traders
Full-screen chart
Technical analysis trends ALEXION PHARMACEU...
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 162 $
Spread / Average Target 36%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
David Richard Brennan Chief Executive Officer & Director
Leonard Bell Chairman
Julie O'Neill Executive Vice President-Global Operations
David John Anderson Chief Financial Officer & Executive Vice President
Martin MacKay Executive VP, Global Head-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ALEXION PHARMACEUTICAL..-3.12%26 691
BIOGEN INC4.89%59 436
CSL LIMITED22.30%42 604
BIOMARIN PHARMACEUTICA..7.56%15 252
GRIFOLS SA19.52%15 171
CHONGQING ZHIFEI BIOLO..--.--%4 243
More Results